215 related articles for article (PubMed ID: 25106775)
1. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort.
Hardikar S; Onstad L; Song X; Wilson AM; Montine TJ; Kratz M; Anderson GL; Blount PL; Reid BJ; White E; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2014 Nov; 23(11):2393-403. PubMed ID: 25106775
[TBL] [Abstract][Full Text] [Related]
2. Leukocyte telomere length predicts cancer risk in Barrett's esophagus.
Risques RA; Vaughan TL; Li X; Odze RD; Blount PL; Ayub K; Gallaher JL; Reid BJ; Rabinovitch PS
Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2649-55. PubMed ID: 18086770
[TBL] [Abstract][Full Text] [Related]
3.
Fang HY; Münch NS; Schottelius M; Ingermann J; Liu H; Schauer M; Stangl S; Multhoff G; Steiger K; Gerngroß C; Jesinghaus M; Weichert W; Kühl AA; Sepulveda AR; Wester HJ; Wang TC; Quante M
Clin Cancer Res; 2018 Mar; 24(5):1048-1061. PubMed ID: 29208671
[No Abstract] [Full Text] [Related]
4. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
5. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas.
Corley DA; Mehtani K; Quesenberry C; Zhao W; de Boer J; Weiss NS
Gastroenterology; 2013 Aug; 145(2):312-9.e1. PubMed ID: 23673354
[TBL] [Abstract][Full Text] [Related]
6. The impact of lifestyle on Barrett's Esophagus: A precursor to esophageal adenocarcinoma.
Navab F; Nathanson BH; Desilets DJ
Cancer Epidemiol; 2015 Dec; 39(6):885-91. PubMed ID: 26519660
[TBL] [Abstract][Full Text] [Related]
7. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma.
Duggan C; Onstad L; Hardikar S; Blount PL; Reid BJ; Vaughan TL
Clin Gastroenterol Hepatol; 2013 Aug; 11(8):934-43. PubMed ID: 23466711
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal study of insulin-like growth factor, insulin-like growth factor binding protein-3, and their polymorphisms: risk of neoplastic progression in Barrett's esophagus.
Siahpush SH; Vaughan TL; Lampe JN; Freeman R; Lewis S; Odze RD; Blount PL; Ayub K; Rabinovitch PS; Reid BJ; Chen C
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2387-95. PubMed ID: 18006928
[TBL] [Abstract][Full Text] [Related]
9. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.
Dong LM; Kristal AR; Peters U; Schenk JM; Sanchez CA; Rabinovitch PS; Blount PL; Odze RD; Ayub K; Reid BJ; Vaughan TL
Nutr Cancer; 2008; 60(1):39-48. PubMed ID: 18444134
[TBL] [Abstract][Full Text] [Related]
10. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
[TBL] [Abstract][Full Text] [Related]
11. Circulating Levels of Inflammatory and Metabolic Biomarkers and Risk of Esophageal Adenocarcinoma and Barrett Esophagus: Systematic Review and Meta-analysis.
Xie SH; Rabbani S; Ness-Jensen E; Lagergren J
Cancer Epidemiol Biomarkers Prev; 2020 Nov; 29(11):2109-2118. PubMed ID: 32855267
[TBL] [Abstract][Full Text] [Related]
12. Immune determinants of Barrett's progression to esophageal adenocarcinoma.
Lagisetty KH; McEwen DP; Nancarrow DJ; Schiebel JG; Ferrer-Torres D; Ray D; Frankel TL; Lin J; Chang AC; Kresty LA; Beer DG
JCI Insight; 2021 Jan; 6(1):. PubMed ID: 33290281
[TBL] [Abstract][Full Text] [Related]
13. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis.
Böttger TC; Youssef V; Dutkowski P; Maschek H; Brenner W; Junginger T
Cancer; 1998 Sep; 83(6):1074-80. PubMed ID: 9740070
[TBL] [Abstract][Full Text] [Related]
14. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
[TBL] [Abstract][Full Text] [Related]
15. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
16. Barrett's surveillance identifies patients with early esophageal adenocarcinoma.
Wong T; Tian J; Nagar AB
Am J Med; 2010 May; 123(5):462-7. PubMed ID: 20399324
[TBL] [Abstract][Full Text] [Related]
17. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses-a population-based cohort study.
Solaymani-Dodaran M; Logan RF; West J; Card T
Am J Gastroenterol; 2005 Dec; 100(12):2616-21. PubMed ID: 16393209
[TBL] [Abstract][Full Text] [Related]
18. Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus.
Rygiel AM; Milano F; Ten Kate FJ; Schaap A; Wang KK; Peppelenbosch MP; Bergman JJ; Krishnadath KK
Cancer Epidemiol Biomarkers Prev; 2008 Jun; 17(6):1380-5. PubMed ID: 18559552
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma.
Wu X; Ajani JA; Gu J; Chang DW; Tan W; Hildebrandt MA; Huang M; Wang KK; Hawk E
Cancer Prev Res (Phila); 2013 Mar; 6(3):196-205. PubMed ID: 23466817
[TBL] [Abstract][Full Text] [Related]
20. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
Thrift AP
Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
